NovoCure Limited Ordinary Shares (NVCR) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCR trades at $17.60 with a market cap of $2.02B and a P/E ratio of -14.46. NVCR moved +4.29% today. Year to date, NVCR is +28.90%; over the trailing twelve months it is -2.47%. Its 52-week range spans $9.82 to $34.13. Analyst consensus is buy with an average price target of $26.17. Rallies surfaces NVCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Japan Grants National Insurance Reimbursement for Optune Lua NSCLC Treatment: Japan’s Ministry of Health, Labour and Welfare approved National Health Insurance reimbursement for Optune Lua in adult patients with unresectable, advanced or recurrent non-small cell lung cancer after platinum-based chemotherapy. It is indicated with PD-1/PD-L1 inhibitors, broadening patient access to tumor treating fields in Japan’s roughly 100,000 annual NSCLC cases.
| Metric | Value |
|---|---|
| Price | $17.60 |
| Market Cap | $2.02B |
| P/E Ratio | -14.46 |
| EPS | $-1.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.13 |
| 52-Week Low | $9.82 |
| Volume | 29 |
| Avg Volume | 0 |
| Revenue (TTM) | $655.35M |
| Net Income | $-136.23M |
| Gross Margin | 74.54% |
6 analysts cover NVCR: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $26.17.